Pfizer India

Its cost of materials consumed fell 2.1% to Rs 94.4 crore, accounting for about 21% of total expenses in the quarter

"There's no editors anymore," Biden added. "There's no editors. How do we expect kids to be able to understand what is at stake?"

Over the past 14 years, Sridhar has led a number of key leadership positions in Pfizer, including serving as the Chief Financial Officer for a period of eight years

The centre integrates two essential functions under the export-oriented undertaking of Pfizer: Pharmaceutical Sciences (PharmSci) and Global Technology and Engineering (GT&E) Centre of Excellence.

Pfizer is near its long-term support, which it has defended for the last five years. A rebound can trigger a 10 per cent upside for the stock.

Announcing the appointment, S Sridhar, the managing director of the company, said with Pradip Shah's elevation as the chairman, the firm will work closely with him on matters of strategic importance

The broader markets logged smart gains for the third straight trading session; Advancing shares outnumbered declining stocks in nearly 2:1 ratio on the BSE

Pfizer beat third-quarter expectations and raised its 2021 forecast again even as sales of its top product, the COVID-19 vaccine Comirnaty, slipped in the U.S.

Sources close to the developments had indicated earlier that the price for India could be below $10 per dose, or the lowest in the world

"We have also helped expedite the introduction of Sputnik-V vaccines," the external affairs ministry spokesperson Arindam Bagchi told ANI.

Countries like the US have granted these vaccine makers immunity where they cannot be sued for any adverse effects.

Pfizer CEO has said a 3rd booster shot likely within a year of vaccination

Pfizer had a meeting with India's drugs regulator on Wednesday and the decision was made after that, the company said.

The company's Indian arm has sought emergency use authorisation (EUA) for the Pfizer/BioNTech vaccine against Covid-19 in the country from the Indian drug regulator.

Pfizer India has become the first pharma company to seek an emergency-use authorisation for its coronavirus vaccine in the country from DCGI

Pfizer has not yet applied for holding clinical trials on Indian volunteers

The U.K. had long signaled it would move fast on any promising vaccine candidate

All that happened in the markets today

Pfizer and Germany's BioNTech are in a race with companies including AstraZeneca Plc, Moderna Inc. to come up with a safe and effective vaccine against Covid-19

The eligibility of stock inclusion in the derivatives / F&O segment is based on the criteria laid down by market regulator Sebi.